Hemophilia B – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Hemophilia B is an uncommon congenital blood disorder characterized by a clotting factor IX (FIX) deficiency, resulting in spontaneous bleeding episodes, particularly in joints, and delayed blood clotting during external bleeding incidents. Repeated joint bleeding can lead to long-term joint deterioration, physical limitations, the necessity for joint replacements, chronic pain, and a diminished quality of life (QoL). The level of circulating FIX determines the severity of Hemophilia B (HB). The treatment approach revolves around FIX replacement therapy, which can be administered either preventively to avert bleeding episodes or reactively after a bleeding episode, known as “on-demand” treatment. Prophylactic FIX therapy is regarded as the standard of care for patients with severe and moderately severe HB. FIX is administered through intravenous injections in either standard half-life (SHL) or extended half-life (EHL) treatments every 2–3 or 7–14 days. However, the frequent infusions required by FIX treatment can impose a significant treatment burden, potentially affecting adherence and clinical effectiveness. The most prevalent complication of hemophilia is attributed to bleeding episodes. Repeated hemarthrosis leads to inflammation and hypertrophy of the synovial membrane, ultimately causing destructive arthropathy. Other complications include intracranial hemorrhages following minor trauma, hypovolemic shock events due to bleeding in the iliopsoas muscle, and airway obstruction due to retropharyngeal bleeding.

Thelansis’s “Hemophilia B Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hemophilia B treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Hemophilia B across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Hemophilia B Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Hemophilia B – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Hemophilia B, Hemophilia B market outlook, Hemophilia B competitive landscape, Hemophilia B market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)